Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France

Prostate Cancer and Prostatic Diseases volume 4, pages 124–131 (2001)Cite this article

Abstract

The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extracted from the THALES database. Special attention was given to the use of medical therapy and switch rates (ie change to another or combination with another drug). In real life practice (RLP) French GPs predominantly utilise α1-adrenoceptor antagonists for the treatment of LUTS. This is in agreement with available evidence from randomised controlled trials (RCTs) with different medical therapies (α1-adrenoceptor antagonists, finasteride, plant extracts). On the contrary, the relatively high usage of phytotherapy might be explained by traditional and personal preferences. Using purely descriptive statistics, newer α1-adrenoceptor antagonists, alfuzosin and tamsulosin, seem to be the most frequently prescribed medical therapy for new patients and are, moreover, associated with a low switch rate.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sagnier P-P et al Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994 151 1266–1270.

    Article  CAS  Google Scholar 

  2. Chapple CR. Pharmacotherapy for benign prostatic hyperplasia—the potential for α-adrenoceptor subtype-specific blockade. Br J Urol 1998 81 (Suppl 1): 34–47.

    Article  Google Scholar 

  3. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996 48 398–405.

    Article  CAS  Google Scholar 

  4. Lepor H et al The efficacy of terazosin finasteride, or both in benign prostatic hyperplasia. New Engl J Med 1996 335 533–539.

    Article  CAS  Google Scholar 

  5. Debruyne FMJ et al Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998 34 169–175.

    Article  CAS  Google Scholar 

  6. Kirby R et al Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial. J Urol 1999 161 (Suppl): 266 (abs. 1027).

    Google Scholar 

  7. Lepor H et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998 160 1358–1367.

    Article  CAS  Google Scholar 

  8. Berges RR et al. Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995 345 1529–1532.

    Article  CAS  Google Scholar 

  9. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebocontrolled, double-blind clinical trial of β-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 1997 80 427–432.

    Article  CAS  Google Scholar 

  10. Carraro J-C et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 1996 29 241–242.

    Article  Google Scholar 

  11. Denis LJ. Editorial review of `comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients'. Prostate 1996 29 241–242.

    Article  Google Scholar 

  12. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999 36 1–13.

    Article  CAS  Google Scholar 

  13. Holtgrewe HL et al. The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia. In: Denis L et al (eds). Proceedings of the 4th International Consultation on BPH. Plymbridge Distributors Ltd: Plymouth 1998 63–81.

    Google Scholar 

  14. Lukacs B. Management of symptomatic BPH in France: who is treated and how? Eur Urol 1999 36 (Suppl 3): 14–20.

    Article  Google Scholar 

  15. Coffey DS. Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol 1998 81 (Suppl 1): 1–5.

    Article  Google Scholar 

  16. Journal Officiel de la République Française. 1995 5 mars 3493–3504. Arrêté du 3 mars 1995. Références médicales opposables. Thème XXI:3500–1.

  17. Denis L et al. Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L et al (eds). Proceedings of the 4th International Consultation on BPH. Plymbridge Distributors Ltd: Plymouth 1998 669–684.

    Google Scholar 

  18. Farmer RDT et al. Changes in the patterns of management of benign prostatic hyperplasia in the United Kingdom: 1991–1998. Eur Urol 2000 37 (Suppl 2): 118 (abstract 471).

    Google Scholar 

  19. Dreikorn K et al. Other medical therapies. In: Denis L et al (eds). Proceedings of the 4th International Consultation on BPH. Plymbridge Distributors Ltd: Plymouth 1998 633–659.

    Google Scholar 

  20. Abbou CC et al. Alfuzosin, an uroselective alpha 1 blocker versus Pygeum africanum, a plant extract: a randomized controlled trial in patients with symptomatic benign prostatic hypertrophy (BPH). Eur Urol 1996 30 (Suppl 2): 77 (abstract 241).

    Google Scholar 

  21. Grasso M et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995 48 97–103.

    CAS  PubMed  Google Scholar 

  22. Andersen JT et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997 49 839–845.

    Article  CAS  Google Scholar 

  23. McConnell JD et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl J Med 1998 338 557–563.

    Article  CAS  Google Scholar 

  24. Abrams P et al. Tamsulosin, a selective α1C-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br J Urol 1995 76 325–336.

    Article  CAS  Google Scholar 

  25. Chapple CR et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996 29 155–167.

    CAS  PubMed  Google Scholar 

  26. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998 51 901–906.

    Article  CAS  Google Scholar 

  27. Michel MC et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 1998 160 784–791.

    Article  CAS  Google Scholar 

  28. Buzelin JM et al, for the European Tamsulosin Study Group. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997 80 597–605.

    Article  CAS  Google Scholar 

  29. Lee E, Lee C. Clinical comparison of selective and non-selective α1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997 80 606–611.

    Article  CAS  Google Scholar 

  30. Na YJ, Guo YL, Gu F-L and the Chinese Tamsulosin Study Group. Clinical comparison of selective and non-selective alpha1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. J Med 1998 29 289–303.

    CAS  PubMed  Google Scholar 

  31. De Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998 33 481–488.

    Article  CAS  Google Scholar 

  32. Stoevelaar HJ et al. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference? J Urol 1999 161 133–138.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to express our gratitude to Ismar Healthcare NV (Belgium) for their support in the editing of this manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, L'Institut Mutualiste Montsouris, Paris, France

    G Vallancien

  2. BKL THALES, Paris, France

    P Pariente

Authors
  1. G Vallancien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Pariente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Vallancien.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vallancien, G., Pariente, P. Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France. Prostate Cancer Prostatic Dis 4, 124–131 (2001). https://doi.org/10.1038/sj.pcan.4500517

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500517

Keywords

This article is cited by

Search

Advanced search

Quick links